Appetite-curbing treatments and weight-loss supplements are taking the world by storm. In particular, a number of diabetes and obesity medications developed by Novo Nordisk (NYSE: NVO) and Eli Lilly are experiencing surging demand. Novo Nordisk is a Danish pharmaceutical company behind the wildly popular drugs Ozempic, Wegovy, Rybelsus, and Saxenda. Chances are you've seen commercials or heard the catchy jingles for some of these treatments.

While weight-loss supplements have been around for a long time, Novo Nordisk's and Eli Lilly's treatments are still fairly new to market. Nonetheless, each of these pharma giants is generating billions of dollars in sales based on the global popularity of the medications. With so many people flocking to take these drugs and seemingly unlimited marketing budgets, is it reasonable to believe that Ozempic and similar treatments will put a dent in the food and beverage industry?

(NASDAQ: PEP) is one of the largest, most iconic soda and snack brands in the world. The company just reported earnings, and its CFO directly addressed Ozempic. Let's explore what Pepsi's management told investors; you may be surprised.

Continue reading

Source Fool.com